TY - JOUR AU - Prewett, M. AU - Rockwell, P. AU - Rockwell, R. F. AU - Giorgio, N. A. AU - Mendelsohn, J. AU - Scher, H. I. PY - 1996 DA - 1996// TI - The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma JO - J Immunother Emphasis Tumor Immunol VL - 19 UR - https://doi.org/10.1097/00002371-199611000-00006 DO - 10.1097/00002371-199611000-00006 ID - Prewett1996 ER - TY - JOUR AU - Riemer, A. B. AU - Kurz, H. AU - Klinger, M. AU - Scheiner, O. AU - Zielinski, C. C. AU - Jensen-Jarolim, E. PY - 2005 DA - 2005// TI - Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies JO - J Natl Cancer Inst VL - 97 UR - https://doi.org/10.1093/jnci/dji373 DO - 10.1093/jnci/dji373 ID - Riemer2005 ER - TY - JOUR AU - Kawaguchi, Y. AU - Kono, K. AU - Mimura, K. AU - Sugai, H. AU - Akaike, H. AU - Fujii, H. PY - 2007 DA - 2007// TI - Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma JO - Int J Cancer VL - 120 UR - https://doi.org/10.1002/ijc.22370 DO - 10.1002/ijc.22370 ID - Kawaguchi2007 ER - TY - JOUR AU - Wang, W. AU - Erbe, A. K. AU - Hank, J. A. AU - Morris, Z. S. AU - Sondel, P. M. PY - 2015 DA - 2015// TI - NK cell-mediated antibody-dependent cellular cytotoxicity in Cancer immunotherapy JO - Front Immunol VL - 6 ID - Wang2015 ER - TY - JOUR AU - Srivastava, R. M. AU - Lee, S. C. AU - Andrade Filho, P. A. AU - Lord, C. A. AU - Jie, H. B. AU - Davidson, H. C. PY - 2013 DA - 2013// TI - Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-12-2426 DO - 10.1158/1078-0432.CCR-12-2426 ID - Srivastava2013 ER - TY - JOUR AU - Bonner, J. A. AU - Harari, P. M. AU - Giralt, J. AU - Azarnia, N. AU - Shin, D. M. AU - Cohen, R. B. PY - 2006 DA - 2006// TI - Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck JO - N Engl J Med VL - 354 UR - https://doi.org/10.1056/NEJMoa053422 DO - 10.1056/NEJMoa053422 ID - Bonner2006 ER - TY - JOUR AU - Vermorken, J. B. AU - Trigo, J. AU - Hitt, R. AU - Koralewski, P. AU - Diaz-Rubio, E. AU - Rolland, F. PY - 2007 DA - 2007// TI - Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2006.06.7447 DO - 10.1200/JCO.2006.06.7447 ID - Vermorken2007 ER - TY - JOUR AU - Morgillo, F. AU - Della Corte, C. M. AU - Fasano, M. AU - Ciardiello, F. PY - 2016 DA - 2016// TI - Mechanisms of resistance to EGFR-targeted drugs: lung cancer JO - ESMO Open VL - 1 UR - https://doi.org/10.1136/esmoopen-2016-000060 DO - 10.1136/esmoopen-2016-000060 ID - Morgillo2016 ER - TY - JOUR AU - Zhao, B. AU - Wang, L. AU - Qiu, H. AU - Zhang, M. AU - Sun, L. AU - Peng, P. PY - 2017 DA - 2017// TI - Mechanisms of resistance to anti-EGFR therapy in colorectal cancer JO - Oncotarget. VL - 8 ID - Zhao2017 ER - TY - JOUR AU - Perisanidis, C. PY - 2017 DA - 2017// TI - Prevalence of EGFR tyrosine kinase domain mutations in head and neck squamous cell carcinoma: cohort study and systematic review JO - In Vivo VL - 31 UR - https://doi.org/10.21873/invivo.11020 DO - 10.21873/invivo.11020 ID - Perisanidis2017 ER - TY - JOUR AU - Boeckx, C. AU - Weyn, C. AU - Bempt, I. AU - Deschoolmeester, V. AU - Wouters, A. AU - Specenier, P. PY - 2014 DA - 2014// TI - Mutation analysis of genes in the EGFR pathway in head and neck cancer patients: implications for anti-EGFR treatment response JO - BMC Res Notes VL - 7 UR - https://doi.org/10.1186/1756-0500-7-337 DO - 10.1186/1756-0500-7-337 ID - Boeckx2014 ER - TY - JOUR AU - Gao, J. AU - Ulekleiv, C. H. AU - Halstensen, T. S. PY - 2016 DA - 2016// TI - Epidermal growth factor (EGF) receptor-ligand based molecular staging predicts prognosis in head and neck squamous cell carcinoma partly due to deregulated EGF- induced amphiregulin expression JO - J Exp Clin Cancer Res VL - 35 UR - https://doi.org/10.1186/s13046-016-0422-z DO - 10.1186/s13046-016-0422-z ID - Gao2016 ER - TY - JOUR AU - Hatakeyama, H. AU - Cheng, H. AU - Wirth, P. AU - Counsell, A. AU - Marcrom, S. R. AU - Wood, C. B. PY - 2010 DA - 2010// TI - Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma JO - PLoS One VL - 5 UR - https://doi.org/10.1371/journal.pone.0012702 DO - 10.1371/journal.pone.0012702 ID - Hatakeyama2010 ER - TY - JOUR AU - Tinhofer, I. AU - Klinghammer, K. AU - Weichert, W. AU - Knodler, M. AU - Stenzinger, A. AU - Gauler, T. PY - 2011 DA - 2011// TI - Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment JO - Clin Cancer Res VL - 17 UR - https://doi.org/10.1158/1078-0432.CCR-10-3338 DO - 10.1158/1078-0432.CCR-10-3338 ID - Tinhofer2011 ER - TY - JOUR AU - Braig, F. AU - Kriegs, M. AU - Voigtlaender, M. AU - Habel, B. AU - Grob, T. AU - Biskup, K. PY - 2017 DA - 2017// TI - Cetuximab resistance in head and neck Cancer is mediated by EGFR-K521 polymorphism JO - Cancer Res VL - 77 UR - https://doi.org/10.1158/0008-5472.CAN-16-0754 DO - 10.1158/0008-5472.CAN-16-0754 ID - Braig2017 ER - TY - JOUR AU - Sok, J. C. AU - Coppelli, F. M. AU - Thomas, S. M. AU - Lango, M. N. AU - Xi, S. AU - Hunt, J. L. PY - 2006 DA - 2006// TI - Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting JO - Clin Cancer Res VL - 12 UR - https://doi.org/10.1158/1078-0432.CCR-06-0913 DO - 10.1158/1078-0432.CCR-06-0913 ID - Sok2006 ER - TY - JOUR AU - Li, C. AU - Iida, M. AU - Dunn, E. F. AU - Ghia, A. J. AU - Wheeler, D. L. PY - 2009 DA - 2009// TI - Nuclear EGFR contributes to acquired resistance to cetuximab JO - Oncogene. VL - 28 UR - https://doi.org/10.1038/onc.2009.234 DO - 10.1038/onc.2009.234 ID - Li2009 ER - TY - JOUR AU - Iida, M. AU - Brand, T. M. AU - Starr, M. M. AU - Huppert, E. J. AU - Luthar, N. AU - Bahrar, H. PY - 2014 DA - 2014// TI - Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy JO - Mol Cancer VL - 13 UR - https://doi.org/10.1186/1476-4598-13-242 DO - 10.1186/1476-4598-13-242 ID - Iida2014 ER - TY - JOUR AU - Madoz-Gurpide, J. AU - Zazo, S. AU - Chamizo, C. AU - Casado, V. AU - Carames, C. AU - Gavin, E. PY - 2015 DA - 2015// TI - Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer JO - J Transl Med VL - 13 UR - https://doi.org/10.1186/s12967-015-0633-7 DO - 10.1186/s12967-015-0633-7 ID - Madoz-Gurpide2015 ER - TY - JOUR AU - Brand, T. M. AU - Iida, M. AU - Stein, A. P. AU - Corrigan, K. L. AU - Braverman, C. M. AU - Luthar, N. PY - 2014 DA - 2014// TI - AXL mediates resistance to cetuximab therapy JO - Cancer Res VL - 74 UR - https://doi.org/10.1158/0008-5472.CAN-14-0294 DO - 10.1158/0008-5472.CAN-14-0294 ID - Brand2014 ER - TY - JOUR AU - Kim, S. M. AU - Kim, J. S. AU - Kim, J. H. AU - Yun, C. O. AU - Kim, E. M. AU - Kim, H. K. PY - 2010 DA - 2010// TI - Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells JO - Cancer Lett VL - 296 UR - https://doi.org/10.1016/j.canlet.2010.04.006 DO - 10.1016/j.canlet.2010.04.006 ID - Kim2010 ER - TY - JOUR AU - Taylor, R. J. AU - Chan, S. L. AU - Wood, A. AU - Voskens, C. J. AU - Wolf, J. S. AU - Lin, W. PY - 2009 DA - 2009// TI - FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck JO - Cancer Immunol Immunother VL - 58 UR - https://doi.org/10.1007/s00262-008-0613-3 DO - 10.1007/s00262-008-0613-3 ID - Taylor2009 ER - TY - JOUR AU - Weidhaas, J. B. AU - Harris, J. AU - Schaue, D. AU - Chen, A. M. AU - Chin, R. AU - Axelrod, R. PY - 2017 DA - 2017// TI - The KRAS-variant and Cetuximab response in head and neck squamous cell Cancer: a secondary analysis of a randomized clinical trial JO - JAMA Oncol VL - 3 UR - https://doi.org/10.1001/jamaoncol.2016.5478 DO - 10.1001/jamaoncol.2016.5478 ID - Weidhaas2017 ER - TY - JOUR AU - Espinosa-Cotton, M. AU - Rodman Iii, S. N. AU - Ross, K. A. AU - Jensen, I. J. AU - Sangodeyi-Miller, K. AU - McLaren, A. J. PY - 2019 DA - 2019// TI - Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma JO - J Immunother Cancer VL - 7 ID - Espinosa-Cotton2019 ER - TY - JOUR AU - Koch, A. T. AU - Love-Homan, L. AU - Espinosa-Cotton, M. AU - Stanam, A. AU - Simons, A. L. PY - 2015 DA - 2015// TI - MyD88-dependent signaling decreases the antitumor efficacy of epidermal growth factor receptor inhibition in head and neck Cancer cells JO - Cancer Res VL - 75 UR - https://doi.org/10.1158/0008-5472.CAN-14-2061 DO - 10.1158/0008-5472.CAN-14-2061 ID - Koch2015 ER - TY - JOUR AU - Dinarello, C. A. PY - 2013 DA - 2013// TI - Overview of the interleukin-1 family of ligands and receptors JO - Semin Immunol VL - 25 UR - https://doi.org/10.1016/j.smim.2013.10.001 DO - 10.1016/j.smim.2013.10.001 ID - Dinarello2013 ER - TY - JOUR AU - Holen, I. AU - Lefley, D. V. AU - Francis, S. E. AU - Rennicks, S. AU - Bradbury, S. AU - Coleman, R. E. PY - 2016 DA - 2016// TI - IL-1 drives breast cancer growth and bone metastasis in vivo JO - Oncotarget. VL - 7 UR - https://doi.org/10.18632/oncotarget.12289 DO - 10.18632/oncotarget.12289 ID - Holen2016 ER - TY - JOUR AU - St John, M. A. PY - 2015 DA - 2015// TI - Inflammatory mediators drive metastasis and drug resistance in head and neck squamous cell carcinoma JO - Laryngoscope. VL - 125 UR - https://doi.org/10.1002/lary.24998 DO - 10.1002/lary.24998 ID - St John2015 ER - TY - STD TI - Stanam A, Gibson-Corley KN, Love-Homan L, Ihejirika N, Simons AL. Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma. Oncotarget. 2016;7:76087–100. ID - ref29 ER - TY - JOUR AU - Sun, Y. AU - Zhu, D. AU - Wang, G. AU - Wang, D. AU - Zhou, H. AU - Liu, X. PY - 2015 DA - 2015// TI - Pro-inflammatory cytokine IL-1beta up-regulates CXC chemokine receptor 4 via notch and ERK signaling pathways in tongue squamous cell carcinoma JO - PLoS One VL - 10 UR - https://doi.org/10.1371/journal.pone.0132677 DO - 10.1371/journal.pone.0132677 ID - Sun2015 ER - TY - JOUR AU - Zhuang, Z. AU - Ju, H. Q. AU - Aguilar, M. AU - Gocho, T. AU - Li, H. AU - Iida, T. PY - 2016 DA - 2016// TI - IL1 receptor antagonist inhibits pancreatic Cancer growth by abrogating NF-kappaB activation JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-14-3382 DO - 10.1158/1078-0432.CCR-14-3382 ID - Zhuang2016 ER - TY - JOUR AU - Eisenthal, A. AU - Rosenberg, S. A. PY - 1989 DA - 1989// TI - The effect of various cytokines on the in vitro induction of antibody-dependent cellular cytotoxicity in murine cells. Enhancement of IL-2-induced antibody-dependent cellular cytotoxicity activity by IL-1 and tumor necrosis factor-alpha JO - J Immunol VL - 142 ID - Eisenthal1989 ER - TY - JOUR AU - Haabeth, O. A. AU - Lorvik, K. B. AU - Yagita, H. AU - Bogen, B. AU - Corthay, A. PY - 2016 DA - 2016// TI - Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells JO - Oncoimmunology. VL - 5 UR - https://doi.org/10.1080/2162402X.2015.1039763 DO - 10.1080/2162402X.2015.1039763 ID - Haabeth2016 ER - TY - JOUR AU - Pullyblank, A. M. AU - Guillou, P. J. AU - Monson, J. R. PY - 1995 DA - 1995// TI - Interleukin 1 and tumour necrosis factor alpha may be responsible for the lytic mechanism during anti-tumour antibody-dependent cell-mediated cytotoxicity JO - Br J Cancer VL - 72 UR - https://doi.org/10.1038/bjc.1995.380 DO - 10.1038/bjc.1995.380 ID - Pullyblank1995 ER - TY - JOUR AU - Fujiwara, T. AU - Grimm, E. A. PY - 1992 DA - 1992// TI - Regulation of lymphokine-activated killer cell induction by human recombinant IL-1 receptor antagonist. Obligate paracrine pathway of IL-1 during lymphokine-activated killer cell induction JO - J Immunol VL - 148 ID - Fujiwara1992 ER - TY - JOUR AU - Ben-Sasson, S. Z. AU - Hogg, A. AU - Hu-Li, J. AU - Wingfield, P. AU - Chen, X. AU - Crank, M. PY - 2013 DA - 2013// TI - IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells JO - J Exp Med VL - 210 UR - https://doi.org/10.1084/jem.20122006 DO - 10.1084/jem.20122006 ID - Ben-Sasson2013 ER - TY - JOUR AU - Ben-Sasson, S. Z. AU - Caucheteux, S. AU - Crank, M. AU - Hu-Li, J. AU - Paul, W. E. PY - 2011 DA - 2011// TI - IL-1 acts on T cells to enhance the magnitude of in vivo immune responses JO - Cytokine. VL - 56 UR - https://doi.org/10.1016/j.cyto.2011.07.006 DO - 10.1016/j.cyto.2011.07.006 ID - Ben-Sasson2011 ER - TY - JOUR AU - Ben-Sasson, S. Z. AU - Hu-Li, J. AU - Quiel, J. AU - Cauchetaux, S. AU - Ratner, M. AU - Shapira, I. PY - 2009 DA - 2009// TI - IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation JO - Proc Natl Acad Sci U S A VL - 106 UR - https://doi.org/10.1073/pnas.0902745106 DO - 10.1073/pnas.0902745106 ID - Ben-Sasson2009 ER - TY - JOUR AU - Bier, H. AU - Hoffmann, T. AU - Haas, I. AU - Lierop, A. PY - 1998 DA - 1998// TI - Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck JO - Cancer Immunol Immunother VL - 46 UR - https://doi.org/10.1007/s002620050475 DO - 10.1007/s002620050475 ID - Bier1998 ER - TY - JOUR AU - Yang, X. AU - Zhang, X. AU - Mortenson, E. D. AU - Radkevich-Brown, O. AU - Wang, Y. AU - Fu, Y. X. PY - 2013 DA - 2013// TI - Cetuximab-mediated tumor regression depends on innate and adaptive immune responses JO - Mol Ther VL - 21 UR - https://doi.org/10.1038/mt.2012.184 DO - 10.1038/mt.2012.184 ID - Yang2013 ER - TY - JOUR AU - Belardelli, F. AU - Ciolli, V. AU - Testa, U. AU - Montesoro, E. AU - Bulgarini, D. AU - Proietti, E. PY - 1989 DA - 1989// TI - Anti-tumor effects of interleukin-2 and interleukin-1 in mice transplanted with different syngeneic tumors JO - Int J Cancer VL - 44 UR - https://doi.org/10.1002/ijc.2910440629 DO - 10.1002/ijc.2910440629 ID - Belardelli1989 ER - TY - JOUR AU - Braunschweiger, P. G. AU - Johnson, C. S. AU - Kumar, N. AU - Ord, V. AU - Furmanski, P. PY - 1988 DA - 1988// TI - Antitumor effects of recombinant human interleukin 1 alpha in RIF-1 and Panc02 solid tumors JO - Cancer Res VL - 48 ID - Braunschweiger1988 ER - TY - JOUR AU - Braunschweiger, P. G. AU - Kumar, N. AU - Constantinidis, I. AU - Wehrle, J. P. AU - Glickson, J. D. AU - Johnson, C. S. PY - 1990 DA - 1990// TI - Potentiation of interleukin 1 alpha mediated antitumor effects by ketoconazole JO - Cancer Res VL - 50 ID - Braunschweiger1990 ER - TY - JOUR AU - Cooper, M. A. AU - Fehniger, T. A. AU - Ponnappan, A. AU - Mehta, V. AU - Wewers, M. D. AU - Caligiuri, M. A. PY - 2001 DA - 2001// TI - Interleukin-1beta costimulates interferon-gamma production by human natural killer cells JO - Eur J Immunol VL - 31 UR - https://doi.org/3.0.CO;2-U DO - 3.0.CO;2-U ID - Cooper2001 ER - TY - JOUR AU - Bossi, P. AU - Bergamini, C. AU - Siano, M. AU - Cossu Rocca, M. AU - Sponghini, A. P. AU - Favales, F. PY - 2016 DA - 2016// TI - Functional genomics uncover the biology behind the responsiveness of head and neck squamous cell Cancer patients to Cetuximab JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-2547 DO - 10.1158/1078-0432.CCR-15-2547 ID - Bossi2016 ER - TY - JOUR AU - Apte, R. N. AU - Voronov, E. PY - 2008 DA - 2008// TI - Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy? JO - Immunol Rev VL - 222 UR - https://doi.org/10.1111/j.1600-065X.2008.00615.x DO - 10.1111/j.1600-065X.2008.00615.x ID - Apte2008 ER - TY - STD TI - Ficlatuzumab. AVEO Oncology. 2018. http://www.aveooncology.com/our-product-candidates/ficlatuzumab/. Accessed 25 June 2019. UR - http://www.aveooncology.com/our-product-candidates/ficlatuzumab/ ID - ref47 ER - TY - JOUR AU - Apte, R. N. AU - Krelin, Y. AU - Song, X. AU - Dotan, S. AU - Recih, E. AU - Elkabets, M. PY - 2006 DA - 2006// TI - Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions JO - Eur J Cancer VL - 42 UR - https://doi.org/10.1016/j.ejca.2006.01.010 DO - 10.1016/j.ejca.2006.01.010 ID - Apte2006 ER - TY - JOUR AU - Gelfo, V. a. l. e. r. i. o. AU - Mazzeschi, M. a. r. t. i. n. a. AU - Grilli, G. i. a. d. a. AU - Lindzen, M. o. s. h. i. t. AU - Santi, S. p. a. r. t. a. c. o. AU - D’Uva, G. a. b. r. i. e. l. e. AU - Győrffy, B. a. l. á. z. s. AU - Ardizzoni, A. n. d. r. e. a. AU - Yarden, Y. o. s. e. f. AU - Lauriola, M. a. t. t. i. a. PY - 2018 DA - 2018// TI - A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy JO - Cancers VL - 10 UR - https://doi.org/10.3390/cancers10100355 DO - 10.3390/cancers10100355 ID - Gelfo2018 ER - TY - JOUR AU - Ridker, P. M. AU - MacFadyen, J. G. AU - Thuren, T. AU - Everett, B. M. AU - Libby, P. AU - Glynn, R. J. PY - 2017 DA - 2017// TI - Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial JO - Lancet. VL - 390 UR - https://doi.org/10.1016/S0140-6736(17)32247-X DO - 10.1016/S0140-6736(17)32247-X ID - Ridker2017 ER - TY - JOUR AU - Vermorken, J. B. AU - Mesia, R. AU - Rivera, F. AU - Remenar, E. AU - Kawecki, A. AU - Rottey, S. PY - 2008 DA - 2008// TI - Platinum-based chemotherapy plus cetuximab in head and neck cancer JO - N Engl J Med VL - 359 UR - https://doi.org/10.1056/NEJMoa0802656 DO - 10.1056/NEJMoa0802656 ID - Vermorken2008 ER - TY - JOUR AU - Thoren, F. B. AU - Anderson, H. AU - Strannegard, O. PY - 2013 DA - 2013// TI - Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications JO - Cancer Immunol Immunother VL - 62 UR - https://doi.org/10.1007/s00262-013-1458-y DO - 10.1007/s00262-013-1458-y ID - Thoren2013 ER -